Publication at First Faculty of Medicine, Third Faculty of Medicine |
2020
Abstract
we have the opportunity to use a number of drugs belonging to the so-called biological treatment. For both the patient and the attending physician, not only the efficacy of the drug but also its safety is important, especially in the long-term horizon.
Risankizumab is the latest available biological molecule, which has proven excellent efficacy as well as long-term safety - the incidence of adverse events, including those of special interest, during the long-term administration of risankizumab was low, as evidenced by integrated data from an extensive analysis of 5,583 patient-years.